Market Cap 428.68M
Revenue (ttm) 850,000.00
Net Income (ttm) -49.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,809.41%
Debt to Equity Ratio 0.00
Volume 2,040,100
Avg Vol 1,049,530
Day's Range N/A - N/A
Shares Out 138.28M
Stochastic %K 36%
Beta 1.49
Analysts Strong Sell
Price Target $13.20

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8099
Address:
80 Guest Street, Suite 601, Boston, United States
King_of_Bio
King_of_Bio Aug. 13 at 12:52 PM
$CMPX Looking good!
0 · Reply
AlertsAndNews
AlertsAndNews Aug. 13 at 2:29 AM
$CMPX Compass Therapeutics Prices $120M Public Offering at $3.00/Share Compass Therapeutics priced an underwritten public offering of 33.29M shares at $3.00 each and 6.71M pre-funded warrants at $2.9999. Gross proceeds are expected to total ~$120M before expenses. The oncology-focused biotech is developing proprietary antibody-based therapeutics for multiple human diseases.
0 · Reply
Groggok
Groggok Aug. 12 at 9:16 PM
$CMPX https://finance.yahoo.com/news/compass-therapeutics-announces-proposed-public-200100037.html
0 · Reply
Senorsiarra7
Senorsiarra7 Aug. 12 at 8:06 PM
$CMPX wtf is even this price action???
2 · Reply
JarvisFlow
JarvisFlow Aug. 12 at 1:01 PM
D. Boral Capital has adjusted their stance on Compass Therapeutics ( $CMPX ), setting the rating to Buy with a target price of 32.
0 · Reply
JarvisFlow
JarvisFlow Aug. 12 at 1:00 PM
Guggenheim updates rating for Compass Therapeutics ( $CMPX ) to Buy, target set at 10 → 12.
0 · Reply
d_risk
d_risk Aug. 12 at 12:24 AM
$CMPX - Compass Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors CMPX flags new risks: global economic uncertainty and tariffs could hurt financials, while potential executive drug pricing actions may threaten future product reimbursement. #Biotechnology #TariffImpact #GlobalEconomicUncertainty #DrugPricingRisk #Pharmaceuticals 🟢 Added 🟠 Removed https://d-risk.ai/CMPX/10-Q/2025-08-11
0 · Reply
Johndoe456
Johndoe456 Aug. 11 at 9:33 PM
0 · Reply
lexlut
lexlut Aug. 11 at 6:58 PM
0 · Reply
birdsong9
birdsong9 Aug. 11 at 4:14 PM
0 · Reply
Latest News on CMPX
Compass Therapeutics Announces Proposed Public Offering

Aug 12, 2025, 4:01 PM EDT - 2 days ago

Compass Therapeutics Announces Proposed Public Offering


Compass Therapeutics to Participate in Upcoming Investor Events

Nov 13, 2024, 8:30 AM EST - 9 months ago

Compass Therapeutics to Participate in Upcoming Investor Events


Compass Therapeutics: Pointing Right At Some Tough Cancers

Jun 20, 2024, 3:14 AM EDT - 1 year ago

Compass Therapeutics: Pointing Right At Some Tough Cancers


Compass Therapeutics Announces CEO Transition

May 28, 2024, 4:10 PM EDT - 1 year ago

Compass Therapeutics Announces CEO Transition


Compass Therapeutics Provides Corporate Update

Jan 5, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Provides Corporate Update


Compass Therapeutics Announces $80 Million Private Placement

Nov 2, 2022, 9:06 AM EDT - 3 years ago

Compass Therapeutics Announces $80 Million Private Placement


King_of_Bio
King_of_Bio Aug. 13 at 12:52 PM
$CMPX Looking good!
0 · Reply
AlertsAndNews
AlertsAndNews Aug. 13 at 2:29 AM
$CMPX Compass Therapeutics Prices $120M Public Offering at $3.00/Share Compass Therapeutics priced an underwritten public offering of 33.29M shares at $3.00 each and 6.71M pre-funded warrants at $2.9999. Gross proceeds are expected to total ~$120M before expenses. The oncology-focused biotech is developing proprietary antibody-based therapeutics for multiple human diseases.
0 · Reply
Groggok
Groggok Aug. 12 at 9:16 PM
$CMPX https://finance.yahoo.com/news/compass-therapeutics-announces-proposed-public-200100037.html
0 · Reply
Senorsiarra7
Senorsiarra7 Aug. 12 at 8:06 PM
$CMPX wtf is even this price action???
2 · Reply
JarvisFlow
JarvisFlow Aug. 12 at 1:01 PM
D. Boral Capital has adjusted their stance on Compass Therapeutics ( $CMPX ), setting the rating to Buy with a target price of 32.
0 · Reply
JarvisFlow
JarvisFlow Aug. 12 at 1:00 PM
Guggenheim updates rating for Compass Therapeutics ( $CMPX ) to Buy, target set at 10 → 12.
0 · Reply
d_risk
d_risk Aug. 12 at 12:24 AM
$CMPX - Compass Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors CMPX flags new risks: global economic uncertainty and tariffs could hurt financials, while potential executive drug pricing actions may threaten future product reimbursement. #Biotechnology #TariffImpact #GlobalEconomicUncertainty #DrugPricingRisk #Pharmaceuticals 🟢 Added 🟠 Removed https://d-risk.ai/CMPX/10-Q/2025-08-11
0 · Reply
Johndoe456
Johndoe456 Aug. 11 at 9:33 PM
0 · Reply
lexlut
lexlut Aug. 11 at 6:58 PM
0 · Reply
birdsong9
birdsong9 Aug. 11 at 4:14 PM
0 · Reply
Groggok
Groggok Aug. 11 at 11:49 AM
$CMPX https://finance.yahoo.com/news/compass-therapeutics-reports-2025-second-110000001.html
0 · Reply
ASarinana
ASarinana Aug. 4 at 12:08 PM
$CMPX according to AI CMPX the last 2 years has been missing earnings by .01 so we are expecting to go down meaning loading time.
1 · Reply
Hunterj17
Hunterj17 Jul. 23 at 6:59 PM
$CMPX only up!
0 · Reply
King_of_Bio
King_of_Bio Jul. 23 at 1:22 PM
$IMUX $GOSS $TSHA $AKBA $CMPX It's bio-season bulls. Here are my favorites as of now. As always, do your own research! Lot of opportunities to make money if know what you're doing. GLTA
1 · Reply
Johndoe456
Johndoe456 Jul. 20 at 3:55 PM
$ABOS $CMPX I LIKE 💰
0 · Reply
lexlut
lexlut Jul. 16 at 7:55 PM
$CMPX 3.22 $
0 · Reply
lexlut
lexlut Jul. 16 at 7:40 PM
$CMPX Waiting for a big Pharma ?
0 · Reply
TheLearnerEarner
TheLearnerEarner Jul. 16 at 3:28 PM
$CMPX ✅ Healthcare - Small Cap - Neutral F-Score: 4/9 🏦 Analysts: 9x buy rating 👨‍🔬 Potential: trading at approximately 96% below estimate of its fair value 💠 Range (12m) $0.87 - $4.08 💰 RSI (14): 68.37 (bullish) 📊 NEWSDESK (article idea is for CMPX only) 📰 https://finance.yahoo.com/news/compass-therapeutics-2-other-promising-120513837.html
0 · Reply
HighRewards
HighRewards Jul. 15 at 6:22 PM
$CMPX The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 53.03% during the next 3 months and, with a 90% probability hold a price between $3.84 and $4.71 at the end of this 3-month period.
0 · Reply
lexlut
lexlut Jul. 15 at 5:42 PM
$CMPX Buyyyy
0 · Reply
lexlut
lexlut Jul. 15 at 1:39 PM
0 · Reply
lexlut
lexlut Jul. 14 at 4:46 PM
$CMPX News oncology ??
0 · Reply